Patients with only dry eye had less severe lid margin abnormalities and orifice plugging along with tear film instability ...

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients ...

Washington University researchers found that raising a molecule called ApoM helps eye cells sweep away harmful cholesterol deposits linked to age-related macular degeneration, potentially preventing ...

A new study reveals that increasing levels of apolipoprotein M (ApoM) may slow or prevent the progression of age-related macular degeneration (AMD), a major cause of blindness in older adults.

A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression ...

13. Autosomal Dominant Optic Atrophy: Seven Major Market Analysis 14. Autosomal Dominant Optic Atrophy Unmet Needs 15. SWOT Analysis 16. KOL Views 17. Market Access and Reimbursement 18. Appendix 19.

Geographic atrophy (GA) is the late stage of age-related macular degeneration (AMD) and may lead to vision loss. Find out about the stages of progression and how you can prepare for them.

Slowing Geographic Atrophy Progression: Oral Antioxidants Show Promise —A post-hoc analysis assessed micronutrient supplementation, including lutein and zeaxanthin, to determine if it slows ...

The publication reported that the child likely suffered from optic atrophy, which, according to the Cleveland Clinic, is a condition that "happens because of long-term damage to optic nerve fibers ...

Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease drug. The round was co-led by ...

Sometimes, optic atrophy occurs due to MS causing optic neuritis, a condition that causes swelling that damages the optic nerve. In this case, vision may return if the inflammation goes away.

Geographic atrophy can cause irreversible damage to your eyes. Syfovre is available as an injection given in the eye by a health care provider. It was the first drug approved by the FDA to treat GA.